Crossmark

CSF1R inhibition rescues tau pathology and neurodegeneration in an A/T/N model with combined AD pathologies, while preserving plaque associated microglia

Crossref DOI link: https://doi.org/10.1186/s40478-021-01204-8

Published Online: 2021-06-08

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lodder, Chritica

Scheyltjens, Isabelle

Stancu, Ilie Cosmin

Botella Lucena, Pablo

Gutiérrez de Ravé, Manuel

Vanherle, Sarah

Vanmierlo, Tim

Cremers, Niels

Vanrusselt, Hannah

Brône, Bert

Hanseeuw, Bernard

Octave, Jean-Noël

Bottelbergs, Astrid

Movahedi, Kiavash http://orcid.org/0000-0002-0826-4399
Dewachter, Ilse http://orcid.org/0000-0001-7202-515X
Funding

Funding for this research was provided by:

Fondation Recherche Alzheimer—Stichting Alzheimer Onderzoek (20180028 & 2020022)

Agentschap Innoveren en Ondernemen

Fonds Wetenschappelijk Onderzoek (G0C6819N & 1259621N)

Innoviris (BB2B 2015-2)
License Information

Text and Data Mining valid from 2021-06-08

Version of Record valid from 2021-06-08
More Information

Article History

Received: 18 May 2021

Accepted: 19 May 2021

First Online: 8 June 2021

Declarations

:

: All experiments were performed by certified researchers according to national and European regulations concerning animal welfare and animal experimentation and were authorized by the Ethics Committee for Animal Research of the University of Hasselt, following national and European guidelines.

: AB is an employee of Janssen Pharmaceutica.

Document is current

Any future updates will be listed below